WHOOP Becomes Official Health and Fitness Wearable Partner and Team Partner of Scuderia Ferrari HP
19.1.2026 14:38:00 EET | Business Wire | Press release
WHOOP, the human performance company, today announced a new, global partnership with Scuderia Ferrari HP as the Official Health and Fitness Wearable Partner and Team Partner. Starting in the 2026 season, Scuderia Ferrari HP cars and drivers will host the WHOOP logo, while WHOOP will be provided to members of the team to unlock insights on their health, recovery, and fitness.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260119602892/en/
This partnership also unlocks a first-of-its-kind integration in which the medical team supporting Scuderia Ferrari HP will work closely with the WHOOP Performance Science team, led by Dr. Kristen Holmes, on enhancing the physical efficiency and recovery for the entire Scuderia Ferrari HP organization. Together, they will work on the foundational elements of health and fitness with a unique human optimization program.
“WHOOP and Scuderia Ferrari HP share the same obsession: performance at the edge,” said Will Ahmed, Founder and CEO of WHOOP. “Scuderia Ferrari HP has spent generations turning data and precision into speed. We’ve done the same for the human system. Bringing those worlds together is a natural fit- and we’re proud to bring this expertise into Formula 1."
This global partnership brings together two brands with legacies built on using data to better understand how to operate at the highest level. With decades of Formula 1 competition and a record-setting legacy, Scuderia Ferrari HP has long integrated human capability, engineering excellence, and continuous optimization, representing a global benchmark for data-driven excellence at the highest level of competition. Combining this approach with the 24/7 continuous health monitoring from WHOOP to support training and human wellbeing. Through this partnership, WHOOP aims to collaborate with the medical team that supports Scuderia Ferrari HP to develop a research paper that brings together the insights uncovered through this work.
“This partnership goes far beyond a logo on the car,” said Dr. Kristen Holmes, Global Head of Human Performance, Principal Science at WHOOP. “By embedding WHOOP across the team, we’re able to deliver continuous, real-world insights into recovery, sleep, strain, and resilience; giving Scuderia Ferrari HP’s drivers, and entire organization the essential data to adapt faster, manage fatigue, and maintain their wellbeing under the extreme conditions of this sport and pressure.”
“The partnership with WHOOP allows us to extend our data-driven approach beyond the car, to aspects more related to the human factor, by combining our expertise in high-performance engineering with WHOOP insights into human health. This collaboration represents a further step in our commitment to innovation and continuous improvement, with the objective of creating the best possible conditions for the team, on and off the track,” said Lorenzo Giorgetti, Chief Racing Revenue Officer of Ferrari.
To access visuals, please visit the Digital Press Kit. To learn more about WHOOP, please visit whoop.com.
About WHOOP:
WHOOP, the human performance company, empowers people to unlock their potential and live longer, healthier lives. The WHOOP membership delivers world-class wearable technology, personalized coaching, and actionable insights across recovery, sleep, training, and health.
WHOOP wearable devices, including WHOOP 5.0 and WHOOP MG, feature groundbreaking innovations such as cardiovascular health screening (including an FDA-cleared ECG), Healthspan to measure Pace of Aging and WHOOP Age, and the first-of-its-kind wearable Blood Pressure Insights.
Founded in 2012 and headquartered in Boston, WHOOP has raised more than $400 million in venture capital and ships to 56 markets worldwide. To learn more or start a one-month free trial, visit whoop.com and connect with WHOOP on Instagram, X, Facebook, LinkedIn, and YouTube.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260119602892/en/
Contacts
Taylor Georgeson
whoop@jacktaylorpr.com
Jack Taylor
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Codethink Opens Early Access to IEC 61508 Mapping for the Eclipse Trustable Software Framework11.3.2026 09:07:00 EET | Press release
EMBEDDED WORLD--Codethink today opened early access to its mapping between the Eclipse Trustable Software Framework (TSF) and IEC 61508, the international standard governing the functional safety of electrical and electronic systems. The mapping establishes a transparent relationship between the engineering principles of the Trustable Software Framework and the objectives defined in IEC 61508. By making this work available as an early preview, Codethink is inviting organisations interested in applying open source approaches to functional safety to review and begin working with the mapping while the work continues to mature. IEC 61508 forms the foundation of many domain-specific safety standards, including ISO 26262 for automotive systems. The early access reflects Codethink’s long-standing commitment to open development of software engineering methods. “This preview release reflects our belief that trust in software must be engineered in the open," said Paul Sherwood, Codethink’s Chair
FERM FOOD Acquires Orkla’s Former Site and Scales Up: Up to 20,000 Tonnes of Fermented Ingredients Per Year11.3.2026 08:00:00 EET | Press release
Danish ingredient producer FERM FOOD is acquiring Orkla’s former manufacturing site in Skovlund, Denmark, effective 1 April 2026. The acquisition provides new production facilities to expand the output of fermented plant-based ingredients for the food industry — driven by export demand that has emerged faster than expected. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260310904877/en/ Jens Legarth (CEO), Rikke Matthiesen (CSO), and Torbjørn Tyndkjær-Thomsen (Food & Process Developer) at FERM FOOD’s new production facilities. “We have outgrown our current facilities. With the Skovlund site, we can supply many more food manufacturers in Denmark and abroad. Global interest has developed faster than we expected — and that is why we are scaling up now,” says Jens Legarth, CEO of FERM FOOD. Once fully ramped up, the new fermentation facility is expected to reach an annual capacity of up to 20,000 tonnes, depending on product mix
Galderma Buys Back Shares Worth CHF 232 Million in the Context of Accelerated Bookbuild Offering11.3.2026 08:00:00 EET | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that it has agreed to repurchase 1.6 million shares at a price of CHF 143.75 per share for a total consideration of CHF 232 million in the context of the accelerated bookbuild offering (“ABO”) of Galderma shares by Sunshine SwissCo GmbH (“EQT”), Abu Dhabi Investment Authority (Private Equities Department) and Auba Investment Pte. Ltd. (all together the “Selling Shareholders”) launched yesterday evening. The repurchase was made at the same price per share determined by the bookbuilding offering. As a result of yesterday evening’s ABO, the Selling Shareholders have fully divested their remaining stake in Galderma. The repurchase, which is expected to settle on March 13 is being financed by Galderma’s existing liquidity on hand and will not affect the company’s ability to deliver on its strategic and financing priorities. The shares will be held in treasury for future use in connection with Galderma's employe
Thales Launches SkyDefender: The Integral Air and Missile Defence Dome With Artificial Intelligence11.3.2026 08:00:00 EET | Press release
As air and missile threats are evolving faster than ever, from slow-moving drones to hypersonic missiles, attacks are becoming increasingly complex, saturating and unpredictable. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260310398606/en/ SkyDefender © Thales Thales SkyDefender provides full protection against all types of air threats, from a few kilometres to several thousands of kilometres: Short-range: for protection of forces, vital assets and sensitive sites: ForceShield creates a real protection bubble against lower layer and surface threats at very short- and short-range, such as drones. Medium-range: for protection at theatre-level defence: SAMP-T NG by eurosam1 with up to 150 km engagement range, including Thales’ powerful Ground Fire radar with 350 km range and 360°/90° coverage against medium-range defence. Long-range: for protection against long-range threats with early-warning capabilities: a unique capacity
Curatis and Neupharma Announce Exclusive Licensing Agreement to Develop and Market Corticorelin (C-PTBE-01) for the Treatment of Peritumoral Brain Edema in Japan11.3.2026 08:00:00 EET | Press release
Curatis Holding AG (SIX: CURN) and Neupharma Co., Ltd. (“Neupharma”), a Japanese pharmaceutical company specializing in oncology, immunology, pulmonology and cardiology disorders, today announce an exclusive license and development agreement for corticorelin (C-PTBE-01) in Japan. Under the terms of the agreement, Neupharma will receive exclusive rights to develop and commercialize corticorelin for the treatment of peritumoral brain edema (PTBE) in Japan. PTBE is a tumor-associated condition for which no approved targeted therapies currently exist. Neupharma will finance and conduct a pivotal clinical trial in Japan to support filing for approval in Japan. Curatis will receive upfront and milestone payments for the achievement of regulatory and commercial targets totaling up to CHF 83.5 million, as well as royalties on future sales in Japan of up to 20%. The agreement stipulates that corticorelin is planned to be introduced in Japan initially for children and adolescents. A meeting with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom